ClinicalTrials.gg
CompletedNCT00462761Updated May 11, 2020Results posted

A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status

A Phase 1 interventional study of AC220 in Acute Myeloid Leukemia, Leukemia and Myelodysplastic Syndrome, sponsored by Daiichi Sankyo. Completed at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-11.

Sponsored by Daiichi Sankyo · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
76
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing quizartinib in Leukemia, Myeloid, Acute — 6 open to participants now, 10 under way, 2 of them phase 3. quizartinib · Leukemia, Myeloid, Acute.

Enrollment
12th of 28
76 · median 69
Started
2007
the only one that year
Phase 1
8 of 28
1 open now
Registered
1st of 28
by date
Lead sponsor
10 of 28
Daiichi Sankyo

Among the 28 studies testing quizartinib in Leukemia, Myeloid, Acute, this one is the 12th largest by enrollment, is the only one that started in 2007, is one of 8 in phase 1, and was the 1st registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

6 of the 28 studies testing quizartinib in Leukemia, Myeloid, Acute are open now, in 9 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About quizartinib

quizartinib: first FDA approval 2023 (VANFLYTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing quizartinib in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

Patients received oral AC220 daily for 14 days to study the side effects, tolerability and best dose for treating relapsed or refractory acute myeloid leukemia, regardless of FLT3 status.

Read the detailed description

This is a multi-center clinical study conducted in the USA and two international sites. This open-label, dose escalation study was designed to characterize the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of orally administered AC220 as a single agent given daily for 14 days. Cohorts of 3 patients received AC220 until dose limiting toxicity was noted (DLT). At that point cohorts expanded to 6 patients until MTD was determined. Patients not experiencing DLT or significant disease progression at Day 15 may have continued receiving AC220 at the discretion of the Investigator and Sponsor. FLT3 positive and negative patients were allowed to participate.

03

Conditions studied

  • Acute Myeloid Leukemia
  • Leukemia
  • Myelodysplastic Syndrome
  • AML
  • MDS

Keywords

  • RTK
  • kinase
  • inhibitor
  • tyrosine
  • acute
  • FLT3
  • AC220
  • pharmacokinetic
  • pharmacokinetics
  • PK
  • pharmacodynamic
  • pharmacodynamics
  • mutations
  • PD
  • receptor
  • class III
  • relapsed
  • refractory
  • t(8;21)
  • q22;q22
  • AML1/ETO
  • t(16;16
  • p13;q22
  • CBFbeta/MYH11
  • inv(16)
  • p13q22
  • 11q23
  • dysplasia
  • myeloid
  • myelomonocytic
  • monoblastic
  • monocytic
  • erythroid
  • erythroleukemia
  • megakaryoblastic
  • basophilic
  • panmyelosis
  • myelofibrosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females age ≥ 18 years;
  2. Histopathologically documented primary or secondary AML, as defined by WHO criteria (Jaffe et al, 2001), confirmed by pathology review at treating institution, meeting at least one of the following:

    1. to at least 1 cycle of induction chemotherapy, or
    2. Relapsed after at least 1 cycle of induction chemotherapy, or
    3. Patient is not, according to the clinical judgment of the Principal Investigator, a candidate for induction chemotherapy due to age, comorbidity, or other factors;
  3. Patients for whom no standard therapies are anticipated to result in a durable remission, or who have failed potentially curative therapy, or who refuse standard therapy or patients for whom there is no known therapy of documented treatment benefit;
  4. (ECOG) performance status of 0-3;
  5. In the absence of rapidly progressing disease, the interval from prior treatment to time of AC220 administration should be at least 2 weeks for cytotoxic agents (other than hydroxyurea, per Section 8.8), or at least 5 half-lives for noncytotoxic agents;
  6. Persistent chronic toxicities from prior chemotherapy or surgery must be less than Grade 2;
  7. Serum creatinine ≤ 2.0 mg/dL;
  8. Total serum ≤ 1.5 × unless considered due to Gilbert's syndrome or leukemic organ involvement;
  9. Serum or ALT ≤ 3.0 × ULN unless considered due to leukemic organ involvement;
  10. Females of must have a negative pregnancy test (urine β-hCG);
  11. Females of childbearing potential and sexually mature males must agree to use a medically accepted method of throughout the study;
  12. Written must be provided.

Exclusion criteria

Exclusion Criteria:

  1. Histologic diagnosis of acute promyelocytic leukemia;
  2. Clinically active central nervous system leukemia;
  3. Persistent toxicity from prior chemotherapy that is Grade 2 or higher by the National Cancer Institute (CTCAE v3);
  4. Bone marrow transplant within 2 months prior to study;
  5. Active, uncontrolled infection;
  6. Major surgery within 4 weeks prior to study;
  7. Radiation therapy within 4 weeks prior to, or concurrent with, study;
  8. positivity;
  9. Active or C or other active liver disease;
  10. Women who are pregnant, lactating, or unwilling to use if of ;
  11. Medical condition, serious intercurrent illness, or other extenuating circumstance that, in the judgment of the Principal Investigator, could jeopardize patient safety or interfere with the objectives of the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    AC220

    Determine safety, tolerability and pharmacokinetic (PK) parameters of AC220

    Drug: AC220

Interventions

  • DrugAC220

    Powder in bottle formulation supplied as 50mg or 350 mg in glass, crimped serum vials. Requires reconstitution by a pharmacist, and must be stored securely and protected from light.

    Also known as: Quizartinib

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Treatment Related Adverse Events Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia

    Time frame: Baseline up to 30 days post last dose

  2. Number of Participants With Treatment-emergent Treatment-related Grade 3 or 4 Adverse Events By At Least 10% of All Participants By Dose Group Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia

    Time frame: Baseline up to 30 days post last dose

Secondary outcomes

  1. Number of Participants Achieving a Best Disease Response by Dose Cohort in Terms of Progressive Disease Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia

    Progressive disease response criteria included doubling of blast count % in bone marrow (biopsy or aspirate) from baseline; considering measurements starting on Study Day 15, doubling of blast count % in blood from baseline; death determined to be related to disease or disease progression; and investigator reported disease progression.

    Time frame: Baseline up to 28 days after the last dose, up to approximately 3 years

  2. Number of Participants Achieving a Best Disease Response by Dose Cohort in Terms of Best Overall Response Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia

    Complete Response (CR) response criteria included either a post-baseline bone marrow (BM) biopsy or aspiration % blasts \<5%, absolute neutrophil count (ANC) \>1×10\^9/L and platelet count \>100×10\^9/L on the same date as the qualifying BM assessment. CRp response included all CR criteria met, except participant did not experience a platelet recovery (ANC recovery required). CRi response included a qualifying BM result, but not an ANC recovery. Participants may or may not have had a platelet recovery and were not required to be transfusion independent. Partial remission (PR) response included a decrease of ≥50% in % blasts in the BM aspirate or biopsy from baseline to a post-baseline result between 5% to 25% in the bone marrow aspirate or biopsy. Nonresponders (NR) had a pre- and 1 or more post-baseline BM assessment carried out, but results did not meet any response criteria. Participants who were not evaluable (NE) did not have at least 14 days of treatment and were not assessed.

    Time frame: Baseline up to 28 days after the last dose, up to approximately 3 years

  3. Number of Participants Achieving a Best Disease Response by Dose Cohort in Terms of Best Overall Response Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia

    Complete Response (CR) response criteria included either a post-baseline bone marrow biopsy or aspiration % blasts \<5%, absolute neutrophil count (ANC) \>1×10\^9/L and platelet count \>100×10\^9/L on the same date as the qualifying bone marrow assessment. CRp response included all CR criteria met except participant did not experience a platelet recovery. Participants must have experienced an ANC Recovery. CRi response included a qualifying bone marrow result, but did not experience an ANC recovery. Participants may or may not have experienced a platelet recovery and were not required to be transfusion independent. Partial remission (PR) response included a decrease of ≥50% in % blasts in the bone marrow aspirate or biopsy from baseline to a post-baseline result between 5% to 25% in the bone marrow aspirate or biopsy. Nonresponders (NR) had a pre- and 1 or more post-baseline bone marrow assessment carried out, but results did not meet any of the CR or PR or progressive disease criteria.

    Time frame: Baseline up to 28 days after the last dose, up to approximately 3 years

  4. Number of Participants With Hematologic Improvement Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia

    Hematologic improvement is summarized in terms of Erythroid Response (HI-E), Platelet Response (HI-P), Neutrophil Response (HI-N), and Hematologic Improvement (HI). For post-treatment results, HI-E major responders had \>2 g/dL increase in hemoglobin for at least 1 result after first treatment and transfusion independent; minor responders 1 to 2 g/dL increase in hemoglobin for at least 1 result post first treatment and a 50% decrease in red blood cell transfusion requirements. For HI-P, major responders had ≥30 × 10\^9/L increase in platelet count and transfusion independent; minor responders had 50% or more increase in platelet count with a net increase between 10 to 30 × 10\^9/L and 50% decrease in platelet transfusion requirements. For HI-N, major responders had an increase in absolute neutrophil count (ANC) of 100% or an absolute increase of more than 0.5 × 10\^9/L (whichever is greater); minor responders had an increase in ANC of 100% but an absolute increase of \<0.5 × 10\^9/L.

    Time frame: Baseline up to 28 days after the last dose, up to approximately 3 years

07

Results

Posted Apr 24, 2020

Participant flow

A total of 76 participants who met all inclusion and no exclusion criteria were enrolled and treated in the study at 4 clinical sites in the United States and 2 sites in the Republic of Georgia.

Participant flow — Overall Study
MilestoneQuizartinib
Started76
Completed0
Not completed76
Withdrew: Adverse event6
Withdrew: Withdrawal by subject9
Withdrew: Physician decision5
Withdrew: Disease progression43
Withdrew: Death12
Withdrew: Other1

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Treatment Related Adverse Events Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia
Time frame:
Baseline up to 30 days post last dose
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Treatment Related Adverse Events Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia
ParticipantsQuizartinib
At Least 1 Treatment-Related Adverse Event39
General disorders & administration site conditions11
Pyrexia2
Fatigue4
Oedema peripheral6
Asthenia1
Chills1
Malaise1
Gastrointestinal disorders21
Nausea12
Diarrhoea6
Vomiting8
Abdominal pain3
Abdominal pain upper2
Dyspepsia3
Constipation1
Abdominal distension2
Gastrointestinal haemorrhage1
Gastrooesophageal reflux disease1
Abdominal discomfort1
Oral mucosal blistering1
Epigastric discomfort1
Retching1
Respiratory, Thoracic, and Mediastinal Disorders2
Haemoptysis1
Dyspnoea exertional1
Blood and Lymphatic System Disorders4
Anaemia3
Thrombocytopenia1
Pancytopenia1
Skin and Subcutaneous Tissue Disorders8
Periorbital odema1
Swelling face1
Alopecia2
Dry skin1
Increased tendency to bruise1
Hair colour changes1
Hidradenitis1
Photosensitivity reaction1
Infections and Infestations1
Pneumonia1
Lung infection1
Metabolism and Nutrition Disorders7
Hypokalaemia2
Anorexia5
Hyperglycaemia1
Hypoalbuminaemia1
Nervous System Disorders12
Headache2
Dizziness1
Dysgeusia8
Hypoaesthesia1
Neuropathy peripheral1
Dysarthria1
Investigations11
Electrocardiogram QT prolonged9
Blood bilirubin increased1
Hepatic enzyme increased1
Psychiatric Disorders1
Insomnia1
Cardiac Disorders1
Right ventricular dysfunction1
Injury, Poisoning, and Procedural Complications1
Contusion1
Eye Disorders1
Eyelid oedema1
Hepatobiliary Disorders3
Hyperbilirubinaemia3
Jaundice1
PrimaryNumber of Participants With Treatment-emergent Treatment-related Grade 3 or 4 Adverse Events By At Least 10% of All Participants By Dose Group Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia
Time frame:
Baseline up to 30 days post last dose
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Treatment-related Grade 3 or 4 Adverse Events By At Least 10% of All Participants By Dose Group Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia
ParticipantsQuizartinib 12-135 mg IDQuizartinib 200-450 mg IDQuizartinib 200-300 mg CDTotal
Nausea : All Grades63312
Nausea : Grade 3-40000
Electrocardiogram QT prolonged : All Grades1089
Electrocardiogram QT prolonged : Grade 3-40044
Dysgeusia : All Grades4138
Dysgeusia : Grade 3-40000
Vomiting : All Grades3328
Vomiting : Grade 3-41001
Anorexia : All Grades3115
Anorexia : Grade 3-41001
Fatigue : All Grades2114
Fatigue : Grade 3-41012
Anaemia : All Grades2103
Anaemia : Grade 3-42103
Hypokalaemia : All Grades2002
Hypokalaemia : Grade 3-41001
Pyrexia : All Grades2002
Pyrexia : Grade 3-41001
Eyelid oedema : All Grades0101
Eyelid oedema : Grade 3-40101
Hypoalbuminaemia : All Grades0101
Hypoalbuminaemia : Grade 3-40101
Lung infection : All Grades0101
Lung infection : Grade 3-40101
Pancytopenia : All Grades1001
Pancytopenia : Grade 3-41001
Photosensitivity reaction : All Grades0011
Photosensitivity reaction : Grade 3-40011
Thrombocytopenia : All Grades0011
Thrombocytopenia : Grade 3-40011
SecondaryNumber of Participants Achieving a Best Disease Response by Dose Cohort in Terms of Progressive Disease Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia

Progressive disease response criteria included doubling of blast count % in bone marrow (biopsy or aspirate) from baseline; considering measurements starting on Study Day 15, doubling of blast count % in blood from baseline; death determined to be related to disease or disease progression; and investigator reported disease progression.

Time frame:
Baseline up to 28 days after the last dose, up to approximately 3 years
Reported as:
Count of participants · Participants
Number of Participants Achieving a Best Disease Response by Dose Cohort in Terms of Progressive Disease Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia
ParticipantsQuizartinib 12 mg IDQuizartinib 18 mg IDQuizartinib 27 mg IDQuizartinib 40 mg IDQuizartinib 60 mg IDQuizartinib 90 mg IDQuizartinib 135 mg IDQuizartinib 200 mg IDQuizartinib 300 mg IDQuizartinib 450 mg IDQuizartinib 200 mg CDQuizartinib 300 mg CDAll Participants
Number of Participants Achieving a Best Disease Response by Dose Cohort in Terms of Progressive Disease Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia22332111224326
SecondaryNumber of Participants Achieving a Best Disease Response by Dose Cohort in Terms of Best Overall Response Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia

Complete Response (CR) response criteria included either a post-baseline bone marrow (BM) biopsy or aspiration % blasts \<5%, absolute neutrophil count (ANC) \>1×10\^9/L and platelet count \>100×10\^9/L on the same date as the qualifying BM assessment. CRp response included all CR criteria met, except participant did not experience a platelet recovery (ANC recovery required). CRi response included a qualifying BM result, but not an ANC recovery. Participants may or may not have had a platelet recovery and were not required to be transfusion independent. Partial remission (PR) response included a decrease of ≥50% in % blasts in the BM aspirate or biopsy from baseline to a post-baseline result between 5% to 25% in the bone marrow aspirate or biopsy. Nonresponders (NR) had a pre- and 1 or more post-baseline BM assessment carried out, but results did not meet any response criteria. Participants who were not evaluable (NE) did not have at least 14 days of treatment and were not assessed.

Time frame:
Baseline up to 28 days after the last dose, up to approximately 3 years
Reported as:
Count of participants · Participants
Number of Participants Achieving a Best Disease Response by Dose Cohort in Terms of Best Overall Response Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia
ParticipantsQuizartinib 12 mg IDQuizartinib 18 mg IDQuizartinib 27 mg IDQuizartinib 40 mg IDQuizartinib 60 mg IDQuizartinib 90 mg IDQuizartinib 135 mg IDQuizartinib 200 mg IDQuizartinib 300 mg IDQuizartinib 450 mg IDQuizartinib 200 mg CDQuizartinib 300 mg CDAll Participants
Overall response01222112226223
composite CR (CR+CRp+CRi)00011001105110
Complete response (CR)0000000000202
CR with incomplete platelet recovery0001000100103
CR with incomplete hematologic recovery0000100010215
Partial remission (PR)01211111121113
Nonresponder (NR)12001123025219
Not evaluable (NE)0310001000218
SecondaryNumber of Participants Achieving a Best Disease Response by Dose Cohort in Terms of Progressive Disease Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia

Progressive disease response criteria included doubling of blast count % in bone marrow (biopsy or aspirate) from baseline; considering measurements starting on Study Day 15, doubling of blast count % in blood from baseline; death determined to be related to disease or disease progression; and investigator reported disease progression.

Time frame:
Baseline up to 28 days after the last dose, up to approximately 3 years
Reported as:
Count of participants · Participants
Number of Participants Achieving a Best Disease Response by Dose Cohort in Terms of Progressive Disease Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia
ParticipantsQuizartinib 12 mg IDQuizartinib 18 mg IDQuizartinib 27 mg IDQuizartinib 40 mg IDQuizartinib 60 mg IDQuizartinib 90 mg IDQuizartinib 135 mg IDQuizartinib 200 mg IDQuizartinib 300 mg IDQuizartinib 450 mg IDQuizartinib 200 mg CDQuizartinib 300 mg CDAll Participants
Number of Participants Achieving a Best Disease Response by Dose Cohort in Terms of Progressive Disease Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia22222010211318
SecondaryNumber of Participants Achieving a Best Disease Response by Dose Cohort in Terms of Best Overall Response Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia

Complete Response (CR) response criteria included either a post-baseline bone marrow biopsy or aspiration % blasts \<5%, absolute neutrophil count (ANC) \>1×10\^9/L and platelet count \>100×10\^9/L on the same date as the qualifying bone marrow assessment. CRp response included all CR criteria met except participant did not experience a platelet recovery. Participants must have experienced an ANC Recovery. CRi response included a qualifying bone marrow result, but did not experience an ANC recovery. Participants may or may not have experienced a platelet recovery and were not required to be transfusion independent. Partial remission (PR) response included a decrease of ≥50% in % blasts in the bone marrow aspirate or biopsy from baseline to a post-baseline result between 5% to 25% in the bone marrow aspirate or biopsy. Nonresponders (NR) had a pre- and 1 or more post-baseline bone marrow assessment carried out, but results did not meet any of the CR or PR or progressive disease criteria.

Time frame:
Baseline up to 28 days after the last dose, up to approximately 3 years
Reported as:
Count of participants · Participants
Number of Participants Achieving a Best Disease Response by Dose Cohort in Terms of Best Overall Response Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia
ParticipantsQuizartinib 12 mg IDQuizartinib 18 mg IDQuizartinib 27 mg IDQuizartinib 40 mg IDQuizartinib 60 mg IDQuizartinib 90 mg IDQuizartinib 135 mg IDQuizartinib 200 mg IDQuizartinib 300 mg IDQuizartinib 450 mg IDQuizartinib 200 mg CDQuizartinib 300 mg CDAll Participants
Overall response01222112216222
Composite CR (CR+CRp+CRi)00011001105110
Complete response (CR)0000000000202
CR with incomplete platelet recovery0001000100103
CR with incomplete hematologic recovery0000100010215
Partial remission01211111111112
Nonresponder12001123025219
SecondaryNumber of Participants With Hematologic Improvement Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia

Hematologic improvement is summarized in terms of Erythroid Response (HI-E), Platelet Response (HI-P), Neutrophil Response (HI-N), and Hematologic Improvement (HI). For post-treatment results, HI-E major responders had \>2 g/dL increase in hemoglobin for at least 1 result after first treatment and transfusion independent; minor responders 1 to 2 g/dL increase in hemoglobin for at least 1 result post first treatment and a 50% decrease in red blood cell transfusion requirements. For HI-P, major responders had ≥30 × 10\^9/L increase in platelet count and transfusion independent; minor responders had 50% or more increase in platelet count with a net increase between 10 to 30 × 10\^9/L and 50% decrease in platelet transfusion requirements. For HI-N, major responders had an increase in absolute neutrophil count (ANC) of 100% or an absolute increase of more than 0.5 × 10\^9/L (whichever is greater); minor responders had an increase in ANC of 100% but an absolute increase of \<0.5 × 10\^9/L.

Time frame:
Baseline up to 28 days after the last dose, up to approximately 3 years
Reported as:
Count of participants · Participants
Number of Participants With Hematologic Improvement Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia
ParticipantsQuizartinib
Erythroid Response (HI-E) Responders35
Erythroid Response (HI-E) Major Responders15
Erythroid Response (HI-E) Minor Responders20
Erythroid Response (HI-E) No Response34
HI-E Participants excluded7
Platelet Response (HI-P) Responders39
Platelet Response (HI-P) Major Responders18
Platelet Response (HI-P) Minor Responders21
Platelet Response (HI-P) No Response29
HI-P Participants excluded8
Neutrophil Response (HI-N) Responders26
Neutrophil Response (HI-N) Major Responders19
Neutrophil Response (HI-N) Minor Responders7
Neutrophil Response (HI-N) No Response24
HI-N Participants excluded26
Hematologic Improvement (HI) Responders60
Hematologic Improvement (HI) Any Major Response38
Hematologic Improvement (HI) Any Minor Response22
HI Participants excluded1

Adverse events

Collected over Adverse events were collected from after initiation of study drug up to 30 days after last dose, up to approximately 3 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Quizartinib 12 mg ID3/3 (100%)1/3 (33.3%)3/3 (100%)
Quizartinib 18 mg ID8/8 (100%)4/8 (50%)8/8 (100%)
Quizartinib 27 mg ID6/6 (100%)1/6 (16.7%)5/6 (83.3%)
Quizartinib 40 mg ID5/5 (100%)3/5 (60%)5/5 (100%)
Quizartinib 60 mg ID5/5 (100%)4/5 (80%)5/5 (100%)
Quizartinib 90 mg ID3/3 (100%)2/3 (66.7%)3/3 (100%)
Quizartinib 135 mg ID5/5 (100%)4/5 (80%)5/5 (100%)
Quizartinib 200 mg ID5/6 (83.3%)3/6 (50%)6/6 (100%)
Quizartinib 300 mg ID4/4 (100%)3/4 (75%)4/4 (100%)
Quizartinib 450 mg ID6/6 (100%)5/6 (83.3%)6/6 (100%)
Quizartinib 200 mg CD16/17 (94.1%)9/17 (52.9%)15/17 (88.2%)
Quizartinib 300 mg CD8/8 (100%)8/8 (100%)8/8 (100%)
Most frequent serious events
Showing 10 of 54
Most frequent serious events
EventQuizartinib 12 mg IDQuizartinib 18 mg IDQuizartinib 27 mg IDQuizartinib 40 mg IDQuizartinib 60 mg IDQuizartinib 90 mg IDQuizartinib 135 mg IDQuizartinib 200 mg IDQuizartinib 300 mg IDQuizartinib 450 mg IDQuizartinib 200 mg CDQuizartinib 300 mg CD
Disease progressionGeneral disorders0/32/80/61/54/51/31/52/61/44/65/173/8
Febrile neutropeniaBlood and lymphatic system disorders0/30/80/62/50/51/32/51/60/40/60/171/8
PyrexiaGeneral disorders0/30/80/60/50/51/30/50/60/40/60/170/8
Neutropenic sepsisInfections and infestations0/30/80/60/50/51/30/51/60/40/60/170/8
Gastrointestinal fungal infectionInfections and infestations1/30/80/60/50/50/30/50/60/40/60/170/8
Abdominal painGastrointestinal disorders1/30/80/60/50/50/30/51/60/40/60/170/8
MelaenaGastrointestinal disorders0/30/80/60/50/51/30/50/60/40/60/171/8
VomitingGastrointestinal disorders1/30/80/60/50/50/31/50/60/40/60/170/8
NauseaGastrointestinal disorders1/30/80/60/50/50/30/50/60/40/60/170/8
HaemoptysisRespiratory, thoracic and mediastinal disorders1/30/80/60/50/50/31/50/60/40/60/170/8
Most frequent other events
Showing 10 of 32
Most frequent other events
EventQuizartinib 12 mg IDQuizartinib 18 mg IDQuizartinib 27 mg IDQuizartinib 40 mg IDQuizartinib 60 mg IDQuizartinib 90 mg IDQuizartinib 135 mg IDQuizartinib 200 mg IDQuizartinib 300 mg IDQuizartinib 450 mg IDQuizartinib 200 mg CDQuizartinib 300 mg CD
Febrile neutropeniaBlood and lymphatic system disorders0/31/81/62/51/53/33/52/60/41/61/173/8
NauseaGastrointestinal disorders1/32/83/61/53/52/32/55/61/44/66/172/8
Disease progressionGeneral disorders0/32/80/61/54/51/31/52/61/44/65/173/8
DiarrhoeaGastrointestinal disorders1/33/81/60/52/51/31/53/61/44/64/173/8
Odema peripheralGeneral disorders1/31/82/61/52/52/32/53/62/41/63/172/8
VomitingGastrointestinal disorders1/31/81/61/50/52/32/52/60/43/67/172/8
PetechiaeSkin and subcutaneous tissue disorders1/31/82/61/50/51/30/52/61/44/63/171/8
CoughRespiratory, thoracic and mediastinal disorders2/32/80/62/50/51/31/52/60/40/61/173/8
HeadacheNervous system disorders0/30/82/60/52/52/31/52/60/40/64/171/8
Abdominal painGastrointestinal disorders2/30/80/60/50/51/31/51/61/42/63/170/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)Quizartinib
Mean56.0 ± 17.1
Age, Customized
Age, Customized(Participants)Quizartinib
<18 years0
18 to 60 years39
61 to 75 years31
>75 years6
Sex: Female, Male
Sex: Female, Male(Participants)Quizartinib
Female30
Male46
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Quizartinib
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American6
White68
More than one race0
Unknown or Not Reported0
08

Study locations

5 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Chemotherapy and Immunotherapy Clinic
    T'Bilisi, Georgia
  • Hematology and Chemotherapy Clinic
    T'bilisi, Georgia
09

References and documents

Publications

  • Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong RC, James J, Levis M. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol. 2013 Oct 10;31(29):3681-7. doi: 10.1200/JCO.2013.48.8783. Epub 2013 Sep 3. PubMed 24002496 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Mar 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2020, 11 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2007
First posted
Apr 19, 2007
Start
Jan 2007
Primary completionActual
Mar 2009
CompletionActual
Dec 2009
Results first posted
Apr 24, 2020
Last update
May 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00462761
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
Apr 19, 2007
Start date
Jan 2007
Primary completion
Mar 2009
Completion
Dec 2009
Results posted
Apr 24, 2020
Last update
May 11, 2020

Study contacts

Clinical Director
study director · Daiichi Sankyo

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Quizartinib

Start the discussion